One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：11
|
作者：
Wang, Michael
Munoz, Javier
Goy, Andre H.
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Milpied, Noel
Fung, Henry C. H.
Topp, Max S.
Houot, Roch
Beitinjaneh, Amer
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Murugappan, Swaminathan
Kloos, Ioana
Reagan, Patrick M.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136382
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study
    Goy, Andre
    Jacobson, Caron A.
    Flinn, Ian W.
    Hill, Brian T.
    Weng, Wen-Kai
    Mountjoy, Luke
    Olalekan, Oluwole
    Zheng, Dan
    Nunes, Ana
    Zhang, Wangshu
    Shen, Rhine R.
    Kloos, Ioana
    Wang, Michael L.
    BLOOD, 2023, 142
  • [32] Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal D.
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Gouill, Steven L. E.
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    BLOOD, 2018, 132
  • [33] ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Mishima, Kazuhiko
    Narita, Yoshitaka
    Nagane, Motoo
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2020, 22 : 57 - 58
  • [34] Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Oliver
    Smith, Stephen
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S316 - S316
  • [35] Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis
    Rule, Simon
    Dreyling, Martin
    Goy, Andre
    Hess, Georg
    Auer, Rebecca
    Kahl, Brad S.
    Hernandez-Rivas, Jose Angel
    Londhe, Anil
    Clow, Fong
    Deshpande, Sanjay
    Parisi, Lori
    Wang, Michael
    BLOOD, 2017, 130
  • [36] Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    Hess, Georg
    Dreyling, Martin
    Oberic, Lucie
    Gine, Eva
    Zinzani, Pier Luigi
    Linton, Kim
    Vilmar, Adam
    Jerkeman, Mats
    Chen, Jenny M. H.
    Ohler, Anke
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Lambert, Jonathan
    Zilioli, Vittorio Ruggero
    Sancho, Juan-Manuel
    Jimenez-Ubieto, Ana
    Fischer, Luca
    Eyre, Toby A.
    Keeping, Sam
    Park, Julie E.
    Wu, James J.
    Nunes, Ana
    Reitan, John
    Wade, Sally W.
    Salles, Gilles
    LEUKEMIA & LYMPHOMA, 2024, 65 (01) : 14 - 25
  • [37] Cost-Effectiveness of KTE-X19 Car T Therapy Following Bruton Tyrosine Kinase Inhibitor Treatment for Relapsed/Refractory Mantle Cell Lymphoma in England
    Maglinte, Gregory A.
    Simons, Claire L.
    Wang, Michael
    Wade, Sally W.
    Brown, Martin
    Petersohn, Svenja
    Bennison, Craig
    Dreyling, Martin
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 195 - 196
  • [38] Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron
    Boissel, Nicolas
    Cassaday, Ryan Daniel
    Forcade, Edouard
    Bishop, Michael Russell
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha Lucia
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Zhou, Lang
    Schuberth, Petra C.
    Adhikary, Sabina
    Masouleh, Behzad Kharabi
    Houot, Roch
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kenderian, Saad S.
    Flinn, Ian W.
    Hill, Brian T.
    Maris, Michael
    Ghia, Paolo
    Byrne, Michael
    Bartlett, Nancy L.
    Pagel, John M.
    Zheng, Yan
    Kanska, Justyna
    Zhang, Wangshu
    Masouleh, Behzad Kharabi
    Granados, Enrique
    Ibarz, Javier Pinilla
    BLOOD, 2022, 140 : 7454 - 7456
  • [40] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
12345